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Significance : Individual patient data analysis of trials across different regional musculoskeletal pain 
sites was used to evaluate course and prognostic factors associated with pain and disability. Overall, 
similarity of outcome predictors across these different pain sites provides supports targeting of 
treatment based on prognostic factors rather than pain site alone. 
 
ABSTRACT  
 
Background: Previous research has identified similar prognostic factors in patients with 
musculoskeletal (MSK) conditions regardless of pain presentation, generating opportunities for 
management based on prognosis rather than specific pain presentation.  
Methods: Data from seven RCTs (2,483 participants) evaluating a range of primary care 
interventions for different MSK pain conditions were used to investigate the course of symptoms 
and explore similarities and differences in predictors of outcome. The value of pain site for 
predicting changes in pain and function was investigated and compared with that of age, gender, 
social class, pain duration, widespread pain, and level of anxiety/depression.  
Results: Over the initial three months of follow-up, changes in mean pain intensity reflected an 
improvement, with little change occurring after this period. Participants with knee pain due to 
osteoarthritis (OA) showed poorer long-term outcome (mean difference in pain reduction at 12 
months -1.85, 95% CI -2.12 to -1.57, compared to low back pain). Increasing age, manual work, 
longer pain duration, widespread pain, and increasing anxiety/depression scores were significantly 
associated with poorer outcome regardless of pain site. Testing of interactions showed some 
variation between pain sites, particularly for knee OA, where age, manual work and pain duration 
were most strongly associated with outcome.  
Conclusions: Despite some differences in prognostic factors for trial participants with knee OA who 
were older and had more chronic conditions, similarity of outcome predictors across regional MSK 
pain sites provides evidence to support targeting of treatment based on prognostic factors rather 
than site of pain. 
 
INTRODUCTION  
The majority of studies on prognosis and management of patients with musculoskeletal (MSK) pain 
have focussed on specific regional pain presentations, such as low back, shoulder, or knee pain. 
Many of these studies show similar findings in terms of clinical characteristics (van der Windt et al 
2008), symptom trajectories (Henschke et al 2012), and prognostic factors (Artus et al 2017; van der 
Windt 2010; Henschke et al 2012). Systematic reviews of prognostic factors have consistently 
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identified pain duration and functional limitations as predictive of poor outcome in upper limb pain 
(Bruls et al 2015; Kooijman et al 2015), low back pain (LBP) (Chou & Shekelle 2010), and knee pain 
attributable to osteoarthritis (OA) (Bastick et al 2015). Observational research has identified 
socioeconomic variables, baseline pain characteristics, and psychological factors that consistently 
predict outcome regardless of pain site (e.g. Valentin et al 2016; Artus et al 2017; de Vos Andersen 
et al 2017). Similarly, prognostic scores for estimating risk of persistent disabling pain, developed 
originally in back pain patients (Von Korff & Miglioretti 2005; Hill et al 2016), have been shown to 
accurately predict outcome across a range of MSK pain sites (Thomas et al 2008; Mallen et al 2013). 
Finally, a brief set of generic prognostic factors (duration of pain episode, pain interference with 
daily activities, presence of multiple-site pain) was found to improve on clinicians’ estimates of 
prognosis in older patients with a range of MSK presentations in primary care (Mallen et al 2013). 
 
Localised, single-site pain is rare with 40-75% of individuals reporting pain at multiple sites (Carnes 
et al 2007; Kalameri et al 2008; van der Windt et al 2008; Hartvigsen et al 2013), which may partly 
explain similarities across pain presentations. A population-based survey (n=3,179) showed 53% of 
those with pain reported pain in more than one site (Kalameri et al 2008), with the number of pain 
sites strongly associated with reduced physical functioning, symptoms of anxiety and depression, 
work absence, and reduced quality of life (Kalameri et al 2009). 
 
These findings support the hypothesis that in patients with MSK pain, generic factors including 
demographics, pain characteristics, psychological or social factors may be more important in the 
prediction of future outcome (prognosis) than the specific pain site or the assumed cause of pain or 
diagnosis. Prognosis rather than diagnosis may provide a framework for clinical practice, integrating 
biological, psychological and social information to support more effective and efficient care (Croft et 
al 2015). This may generate opportunities for the design and evaluation of interventions that target 
potentially modifiable prognostic factors regardless of pain site or diagnosis. This study tested this 
hypothesis by investigating the course of pain and limitations in function in trial participants with 
MSK pain in different sites, identify generic prognostic factors, and explore to what extent the 
association between prognostic factors and outcome in trial participants is modified by pain site. 
Trial data where treatment was randomly allocated was used to reduce the risk of treatment bias in 
this prognostic study.  
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METHODS 
Design and Study Participants 
This study was based on secondary analysis of individual patient data from seven randomised clinical 
trials carried out within the Arthritis Research UK Primary Care Centre (Keele University, UK), 
investigating a range of interventions with patients recruited from general practice, and published 
between 2004 and 2011. Information specific to the trials included in the present study is given 
below, and additional details are reported in Appendix 1. 
Treatment Options for Pain in the Knee (TOPIK) trial: The aim of this three arm trial was to 
investigate the effects of physiotherapist-led advice and exercise (intervention) and enhanced 
pharmacy review (intervention) compared to an advice and exercise leaflet (control) in people aged 
55 and over presenting in general practice with pain and/or stiffness lasting more than three months 
in one or both knees who were followed up at three, six and 12 months. Both interventions showed 
significantly larger short-term improvements in pain and function compared to control (Hay et al 
2006). 
Acupuncture Physiotherapy and Exercise (APEX) trial: The aim of this trial was to investigate whether 
adding acupuncture to a course of physiotherapist-led advice and exercise leads to greater pain 
relief in patients with knee pain (of any duration) attributable to OA (Hay et al 2004). The APEX trial 
included three arms, all delivered by physiotherapists: a course of advice and exercise (control), 
advice and exercise with true acupuncture (true) and advice and exercise with sham acupuncture. 
Participants were followed up at six weeks, six months and 12 months. The primary outcomes 
showed no additional benefit for true compared to sham or control (Foster et al 2007). 
Low Back Pain (LBP) Trial: This trial compared the effects of a course of traditional physiotherapist-
led management including exercise and manual therapy (intervention) with those of a brief course of 
pain management provided by physiotherapists (intervention) in patients with non-specific LBP (of 
less than three months duration). Participants were followed up at three and 12 months with the 
results indicating no significant or clinically important differences between the two treatments (Hay 
et al 2005).  
Screening and Targeted Treatment for Back Pain (STarT Back) trial: This trial compared a stratified 
care approach consisting of prognostic stratification into low, medium and high risk subgroups 
followed by targeted treatment (intervention) with current best care (control) for patients 
presenting with non-specific LBP (of any duration). Changes in back pain-related disability and pain 
catastrophising were investigated at four and 12 months follow-up. The findings showed significantly 
superior pain and function outcomes in the stratified care arm compared to control (Hill et al 2011). 
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Physiotherapy Arthritis Research UK Neck Trial Hands-on and Electrotherapy Research (PANTHER): 
PANTHER investigated the outcomes of physiotherapist-led advice and exercise in addition to 
manual therapy (intervention) and advice and exercise with pulsed shortwave diathermy (PSWD) 
(intervention) compared to advice and exercise alone (control) in patients with neck pain (of more 
than four weeks duration). Outcomes were assessed at six weeks and six months. No significant 
differences were found between the treatment arms (Dziedzic et al 2005). 
SPIRIT (Shoulder Physiotherapy and Injection RandomIsation Trial): This trial in patients with 
unilateral shoulder pain (of more than four weeks duration) compared outcomes of pain and 
function between participants randomly allocated to either a course of physiotherapist led advice, 
manual therapy and ultrasound (as required) (intervention) or corticosteroid injection (intervention). 
Participants were followed up at six weeks, six months and 18 months. The results showed no 
significant differences in outcomes across the treatment arms (Hay et al 2003). 
Tennis Elbow trial: The objective of this three arm trial was to compare the effects of corticosteroid 
injection (active), Non-Steroidal Anti-Inflammatory Drugs (NSAIDs, intervention) and unmarked 
vitamin C (placebo) in patients with elbow pain (of any duration) attributable to lateral epicondylitis 
(tennis elbow) at four weeks, six months and 12 months follow-up. The results showed better 
outcomes for corticosteroid injection at four weeks, however more participants in this group 
showed relapse at long-term follow-up (Hay et al 1999). 
 
Outcome measures  
The outcome measures for all analyses were changes in (1) pain intensity and (2) limitation in 
function. Although most trials used a 0-10 point visual analogue scale (VAS) or numerical rating scale 
(NRS) to assess pain intensity, the trials used different pain-specific instruments to measure 
functional limitation. This outcome was measured with the Western Ontario and McMaster 
Universities Arthritis Index (WOMAC) function score (Bellamy et al 1988) in the knee pain trials 
(TOPIK, APEX); Roland Morris Disability Questionnaire (RMDQ) (Roland & Morris 1983) in the LBP 
trials (STarT Back, LBP trial); Northwick Park Neck Pain Questionnaire (NPPQ) (Leak et al 1994) in the 
neck pain trial (PANTHER); Shoulder Disability Questionnaire (SDQ) (Croft et al 1994) in the shoulder 
pain trial (SPIRIT), and a 1-10 NRS in the Tennis Elbow trial. In all datasets the scores for pain and 
functional limitation were transformed onto a 0-10 scale with higher scores indicating more severe 
pain or functional limitation, to allow comparison of descriptive results across studies and pooling of 
data for analysis. Evaluation of pain and function outcomes was based on change from baseline, and 
hence higher values denote greater improvement in pain/functional limitation.  
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Prognostic factors 
Potential baseline prognostic factors, that were expected to be associated with outcomes of pain 
and disability based on existing evidence, were identified from the available variables within each 
dataset. Variables were subsequently recoded where needed to ensure consistency between 
datasets. Variables included for analysis were pain score (0-10), function score (0-10), age 
(continuous scale), gender, duration of pain episode (less than 1 month, 1-3 months, 3+ months), 
manual work (Manual versus Non-Manual occupation), presence of widespread pain according to 
American College of Rheumatology criteria (Wolfe et al 1990) (yes/no), presence of multisite pain if 
pain at more than one site was reported, and mood problems (none, moderate, extremely anxious 
or depressed, using the anxiety/depression item from EQ5D-3L) (EuroQol Group 1990). The Tennis 
Elbow trial did not collect information on anxiety and depression, and therefore this dataset was 
excluded from analyses of prognostic factors. 
 
Analysis 
Clinical course: To ensure comparable follow-up points, short-term and long-term time points were 
identified for each trial, selecting the scores nearest to three months follow-up as the short-term 
time point, and the scores at 12 months or later as the long-term time point. PANTHER did not 
include scores after six months follow-up and was therefore only included in the analysis of short-
term outcomes. The baseline and follow-up outcome scores data from each of the seven trials were 
then merged. Pain duration did differ between the trials, partly as a result of the different study 
inclusion criteria; three studies (APEX, PANTHER and SPIRIT) did not include patients with pain of less 
than four week’s duration, and the LBP trial did not include patients with pain of more than three 
months duration. In order to describe the course of symptoms within each trial overall, outcome 
scores for pain and function limitation at each follow up point were presented in a graph (Figures 1 
and 2). 
 
Changes from baseline at short- and long-term follow-up were calculated for both pain intensity and 
functional limitation. Linear regression was used to analyse changes in pain and functional limitation. 
Univariable models were computed with pain site (back, knee, shoulder, neck, and elbow) as the 
determinant in order to investigate differences in outcome for these separate pain sites, whilst 
adjusting for baseline pain and functional limitation only (as baseline levels are often found to be the 
strongest predictors of future pain and disability (e.g. Bot et al 2005; van der Waal et al 2005; 
Campbell et al 2013; Gustavsson et al 2013)).  
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Prognostic factors: Additional potential prognostic factors (all listed in Prognostic factors above) 
were then included to investigate which variables predicted outcome regardless of pain site or 
treatment. Analysis of the effectiveness of specific interventions was not an objective of this study, 
but intervention was included in the analysis as a potential confounder. Interventions were broadly 
classified into intervention, sham/placebo, or control depending on the nature of the treatment, 
where participants allocated to control or sham interventions often continued to receive care as 
usual (see trial descriptions above). The use of data from RCTs with random allocation of participants 
reduced the risk of treatment bias (also referred to as the treatment paradox), which may occur in 
prognosis studies using observational data if individuals with more severe or complex disease are 
more likely to receive more intensive treatment. If such treatment is effective, it will influence 
prognosis, and thereby also the association between potential prognostic factors and outcome 
(Schuit et al. 2013). Collinearity was examined by computing a variance inflation factor (VIF) for each 
factor in the model, where a value greater than 10 would indicate potential collinearity.  
 
As data were clustered within trials, further analysis (with all the same prognostic factors included in 
the previous analysis) explored variation in outcomes across pain sites taking into account clustering 
of data within trials using random effects modelling: firstly through random intercept models, and 
secondly by random slope models to investigate the potential effect of clustering within pain sites. 
Comparison between models (random intercept and random slope) was based on a Likelihood-Ratio 
Test (LRT), where a significant difference between the two models implied that a random slope 
model is preferred.  Intraclass Correlation Coefficients (ICCs) were estimated for each model to 
represent the correlation of the outcome within trials. A high ICC would imply that outcome scores 
were highly dependent on trial identification and analysis would require random effect constraints. 
 
Moderation by pain site: Interaction terms (prognostic factor*pain site) for all prognostic factors 
with all pain sites were added to the random effects model (in addition to all the prognostic factors 
previously included). In order to explore to what extent the strength of associations between 
prognostic factors and outcomes varied across pain sites, these interactions of all prognostic factors 
with all pain sites were added to the random effects model one at a time, and in turn (replacing the 
previous interaction). 
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RESULTS 
Participants 
The number of participants from each included trial ranged from 164 to 851, resulting in a total 
sample of 2,651 participants, with individual participants’ data for 2,483 available for analysis. Table 
1 presents baseline characteristics and baseline scores of outcome measures for each of the trials. 
The mean age of participants ranged from 41 to 68 years, and 47% to 64% were female. Widespread 
pain was reported by between 5% and 39% of participants, with the median number of pain sites 
(potential scale: 0-49) varying between 3 and 8 sites across trials. Pain duration varied widely in the 
trial populations, with the APEX trial only including patients with pain of more than three months 
duration, the LBP trial focusing on patients with pain of less than three months duration, and the 
remaining trials including between 29% and 86% of patients who reported pain lasting for more than 
three months. 
 
Course of pain intensity and function 
Mean scores over time for both pain intensity (Figure 1) and functional limitation (Figure 2) show 
considerable variation between trials in terms of short-term improvement in these outcomes, yet in 
all trials most improvement of symptoms occurred over the first three months, with little further 
change over the subsequent 3 to 18 months of follow-up.  
 
Analysis of changes in pain and function adjusted for baseline scores portrayed different 
relationships depending on pain site (Table 2). Participants in the LBP trials showed larger short-term 
improvements in both pain and function compared to those with pain at other body sites, although 
the difference was small, and not statistically significant for pain intensity in LBP participants 
compared to those with shoulder pain. Using LBP as the reference, participants of the shoulder or 
elbow trials showed larger improvements for both pain intensity and function at long-term follow-
up, whereas those with knee pain showed less improvement in pain and function. The mean pain 
intensity score at 12 months (adjusted for differences in baseline values) was almost 2 points higher 
for participants with knee pain compared to LBP. 
 
Prognostic factors 
Increasing age, longer pain duration, manual work, presence of widespread pain, and mood 
problems (moderate/extreme anxiety or depressive symptoms) were significantly associated with 
poor outcome (smaller change in both pain and function), regardless of pain site and adjusted for 
intervention classification for both follow-up time-points, short and long term, with adjusted mean 
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differences ranging between 0.3 and 1.7 (Table 3). Higher levels of functional limitation at baseline 
were associated with larger improvements in function (adjusted mean difference 0.54 and 0.56, 
short- and long-term follow-up, respectively), but appeared to indicate slightly poorer pain 
outcomes (-0.16 and -0.18, respectively). A similar effect was seen for higher baseline levels of pain, 
although the impact on change in function was smaller. Females appeared to have larger 
improvements in long-term function compared to males, adjusted for other potential confounders 
(adjusted mean difference 0.25, 95% CI 0.05, 0.45). There was no evidence of collinearity in either 
model, with all VIF values for each confounder less than 2.10. 
 
The random effects model indicated that ICCs were small, and the model confirmed significant 
variation in outcomes between trials for outcomes of short-term pain intensity (p=0.026) 
(ICC=0.009), long-term pain intensity (p=0.018) (ICC=0.013) but not for short-term functional 
limitation (p=0.062) (ICC=0.008), and variation was not significant for long-term functional limitation 
(p>0.9) (ICC<0.001). Fitting a random slope for pain site showed no significant improvement of the 
models, indicating that there was no significant variation in outcomes across individual trials (other 
than that explained by the fixed effects) i.e. no relevant influence of clustering on outcome 
trajectories (all p-values >0.50), and therefore random effects at trial level was deemed sufficient for 
further analysis. 
 
Variation in prognostic factors across pain sites 
Significant interactions mostly concerned site of pain at the knee (Table 4). Participants with knee 
pain showed stronger associations with poor outcome for baseline levels of pain and function, 
increasing age, longer pain duration, and manual work, although the interaction of pain site with 
manual work was only significant for pain intensity. Few other interactions were found, although in 
participants with shoulder pain, increasing age and male gender were more strongly associated with 
poorer outcomes of pain and/or function compared to LBP (reference category). LBP was used as the 
reference category because of the extensive evidence base regarding its course and prognosis. No 
significant interactions were found for widespread pain and mood problems, indicating that these 
variables had a similar effect on outcome across all pain sites. 
 
DISCUSSION  
This study, using individual participant data from seven randomised clinical trials, showed a similar 
pattern of improvement in pain intensity and functional limitation outcomes regardless of the site of 
MSK pain. An improvement in mean pain intensity and function scores was observed over the initial 
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three-month post-randomisation follow-up period of the trials, after which little further change 
occurred. Despite this similar overall pattern there were significant differences between pain sites in 
terms of the magnitude of improvement at short- and long-term follow-up. Participants with LBP 
showed the largest short-term improvements, whereas those with upper limb pain (shoulder or 
elbow) showed better long-term outcomes compared to other pain sites. Participants with knee pain 
(which were all older adults with pain attributable to OA) showed the least improvement during 
follow-up. In other words, improvement is seen across all pain sites but the magnitude of this 
improvement varies according to pain site. Increasing age, manual work, longer pain duration, 
mood, and presence of widespread pain were significantly associated with poor outcome, but 
testing for interactions showed some variation between pain sites in the strength of associations, 
particularly for knee pain where increased age, manual work and increased pain duration were 
stronger predictors of poor outcome compared to other sites.  
 
Patterns of improvement 
Our findings are consistent with a previous systematic review which investigated the pattern of 
symptom improvement in patients receiving different primary care treatments for non-specific LBP 
(Artus et al 2010). The review found that across a large number of trials and different types of 
treatment, a similar pattern of improvement emerged; rapid improvement within six weeks, 
followed by a slower improvement up to six months post-randomisation. The review authors 
proposed several reasons for these findings, including natural history of LBP, regression to the mean 
in people seeking care when pain levels are high, and the potential influence of variables other than 
specific treatment effect, including patient characteristics (prognostic factors) or therapist effects. 
Our finding that higher baseline pain scores were associated with larger improvements in pain 
despite poorer follow-up function scores (and vice versa), indicates there is room for improvement 
and a potential role of regression to the mean in those with high baseline scores for pain or 
functional limitation. 
 
Although the patterns of pain was similar across pain sites, the present study shows variation in the 
magnitude of improvement across pain sites. The largest differences were found for participants of 
the two knee pain trials who showed poorer outcomes, and stronger associations between some 
prognostic factors (duration, age, manual work) and future outcome. However, these trials included 
people with knee pain attributed to osteoarthritis, reflecting a presentation of pain that is more 
likely to be characterised by persistent or recurrent pain and function over long periods of time, or 
simply by characteristics of the sample such as older age and longer duration of pain. Cohort studies 
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investigating long-term (5-7 year) trajectories of pain and function in people with knee OA have 
identified distinct subgroups with varying long-term symptom trajectories, often strongly associated 
with baseline levels of pain and function. These trajectories were classified as improving in 3-12% 
and as persistent-mild in 28-35% of participants, with other subgroups (40-60%) showing moderate 
to severe symptoms over long periods of time (Collins et al 2014; Nicholls et al 2014; White et al 
2016). This confirms the more persistent course of pain and function in knee OA populations 
compared to other musculoskeletal pain presentations included in our analysis.    
 
Generic prognostic factors 
We did not specifically include trials focusing on people with pain at multiple sites, as we aimed to 
test the hypothesis that factors may predict outcome regardless of the site of pain. However, 
consistent with previous findings from observational studies, a significant proportion of participants 
did have widespread pain: approximately 25% of all trial participants met ACR criteria for 
widespread pain, mainly those with knee pain or LBP. This may have influenced our results regarding 
the interaction between pain site and prognostic factors, but also highlights the importance of 
assessing and investigating more generic aspects of pain presentation and not focusing on the 
regional pain site only. Widespread pain was included in the analyses as a potential prognostic 
factor, so the results reflect the impact of this factor. 
 
The results from our study suggest that clinical decisions regarding treatment should therefore not 
be based on the site of MSK pain only. Croft et al (2015) have recently summarised evidence for a 
prognosis-based rather than a diagnosis-based framework for clinical decision-making, on the basis 
that the former provides a more biopsychosocial perspective and is perhaps more useful in 
presentations which have a less definitive biomedical diagnosis, as is the case for many patients with 
MSK pain. Studies that have investigated the predictive value of diagnostic information in regional 
pain presentations have not found diagnosis to be a strong prognostic factor (Spies-Dorgelo et al 
2008; Chester et al 2016). These findings as well as the results from our study suggest that it is 
important to shift attention towards prognostic evidence when in the management of 
musculoskeletal conditions, rather than focusing on pain site and diagnosis only.  
 
Recent evidence shows that subgrouping LBP patients based on risk of persistent disabling pain and 
matching the subgroups to different treatments is clinically and cost-effective (Hill et al 2011; Foster 
et al 2014). The results of this study add to that evidence, and together they highlight the need to 
develop and test approaches that subgroup MSK pain patients based on their prognosis, and then 
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match them to appropriate treatments. Prospective cohort studies can be used to derive and 
validate prognostic factors or multi-dimensional prognostic models across musculoskeletal pain 
presentations (e.g. Campbell et al 2016), but randomised clinical trials of sufficient size are needed 
to test if prognostic factors can predict a differential response to treatment, and to investigate the 
clinical and cost-effectiveness of stratified care approaches in which prognostic stratification is an 
important driver of treatment selection (Hingorani et al 2013; van der Windt & Dunn 2013; Croft et 
al 2015). 
 
Strengths & Limitations 
The results from this study are based on trial data collected between 1995 and 2008. It could be that 
data from more recent cohorts is different from that analysed here. However, the Artus et al (2014) 
review which included more recent data, from cohorts as well as trials, included age ranges and 
proportions of females that were within the ranges reported in the trials included in the present 
study.  The inclusion criteria, presented in Appendix 1, show to what extent the results can be 
generalised to patients presenting to primary care with pain in various musculoskeletal pain sites. 
Each trial reflects a different target population, but the point of the present study was to investigate 
the predictive value of factors across these different populations, and also across the variations in 
pain and function scores between the different populations. 
 
 
 
Differences in prognostic variables were difficult to resolve, and may have resulted in 
misclassification of exposures (information bias). More precise and consistent assessment of 
prognostic factors could have resulted in more precise estimates of associations. Our study may 
have underestimated the strength of association, although we have no reason to believe that 
misclassification would have resulted in a different direction of effect.  This analysis looked at 
prognostic factors in trial participants (adjusting for intervention), but has not investigated 
predictors of differential treatment response (effect modification). The findings may therefore 
provide information to identify which patients may require further treatment, but not which specific 
treatments may be most beneficial to them. This paper also presents only a small number of trials 
with limited data on prognostic factors, and lack of consistency amongst the measures used to 
assess the prognostic factors and outcomes. Although prognostic factors were a priori selected 
based on existing evidence, the analysis did include a large number of interaction tests, given the 
different outcomes, time points and prognostic factors, which could have resulted in spurious 
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findings. However, the use of IPD from multiple trials is important to obtain a sufficiently large 
sample size to test for a priori-defined interactions (Debray et al 2015), and results were fairly 
consistent across trials.  
 
Finally, while we considered standardising the function scales used as outcome measures we instead 
chose to transform them. As the scales differed across studies, standardisation may have allowed for 
more comparability. However, the distributions of scores across each of the function scales were 
similar (see Table 1) and allowed easier interpretation of the regression coefficients. To our 
knowledge, few studies have assessed and compared prognostic factors across different pain sites, 
in particular using trial data – where effects of treatment are less likely to influence associations 
between prognostic factors and outcome. Our study has added evidence regarding factors that 
predict outcome across different pain sites, which may inform the care for patients with various 
musculoskeletal conditions. The results of this exploratory analysis should be interpreted with 
caution, but they support further investigation of the predictive value and clinical utility of generic 
prognostic factors in patients with MSK pain across a range of pain sites.  
 
Implications 
This study identified two potentially modifiable factors (manual work and mood) that could be 
targeted during treatment. Mood has been found to be modifiable in physiotherapy settings where 
physiotherapists have been trained to target this factor (e.g. Lamb et al 2010; Hill et al 2011), and 
subsequent mediation analyses carried out on both of these trials to investigate how the 
interventions worked identified change in mood as a mediator, further highlighting its importance as 
a treatment target (Mansell et al 2016; Fordham et al 2016). 
 
While work may be assumed to be a more difficult factor to address in clinical practice, a previous 
trial which provided vocational advice to those who were off sick due to LBP was found to 
successfully reduce the number of sick days taken (Wynne-Jones et al 2017). The intervention 
enabled GPs and nurses to refer patients to Vocational Advisors who could assist patients with 
obstacles to returning to work.  
 
 
Conclusions 
Analysis of individual patient data from multiple trials confirms the role of baseline levels of pain and 
function, widespread pain and mood problems as consistent predictors of poor outcome, providing 
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evidence to support prognostic stratification based on these factors, and offering opportunities for 
future investigation of the effectiveness of targeted treatment approaches across pain 
presentations.  
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Table 1: Baseline characteristics of participants of each of the seven trials 
Table 2: Univariable associations between pain site and short and long-term outcomes of change in 
pain and limitation in function# 
Table 3: Multivariable associations (random effects linear regression, accounting for clustering 
within trials) between prognostic factors and outcomes of change in pain and limitation in function#  
Table 4: Significant interactions of pain site with potential prognostic factors (each interaction term 
has been individually added to the multivariable random effects model (random intercept for trial), 
one at the time)  
 
Figure 1. The course of pain intensity (mean scores, 0-10) for each trial  
Figure 2. The course of limitation in function (mean scores, 0-10) for each trial  
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Table 1: Baseline characteristics of participants of each of the seven trials 
 
  APEX 
(Knee) 
TOPIK 
(Knee) 
LBP  
(Back) 
STarT 
Back 
(Back) 
PANTHER 
(Neck) 
SPIRT 
(Shoulder) 
Tennis 
Elbow Trial 
Total 
Number of participants (n) 329 312 394 812 300 205 131 2483 
Age (Mean, SD) 63.1     
(8.7) 
68.0  
(8.1) 
40.5   
(11.7) 
49.5 (14.4) 51.1    (13.8) 57.5   (13.4) 46.6  
(7.9) 
52.9 
(15.0) 
Female gender (n, (%)) 198 (60.2) 200 (64.1) 208 (52.8) 469 (57.8) 185 (61.7) 110 (53.7) 61 (46.6) 1431 (57.6) 
Duration (n, 
(%)) 
Less than 1 month 0 (0)* 11 (4.2) 340 (86.3) 142 (17.5) 14 (4.7) 75 (36.6) 26 (19.9) 608 (25.0) 
1-3 months 0 (0)* 27 (10.3) 53 (13.5) 186 (22.9) 57 (19.0) 70 (34.2) 61 (46.6) 454 (18.7) 
More than 3 
months 
329 (100) 224 (85.5) 1 (0.3) 484 (59.6) 229 (76.3) 60 (29.3) 44 (33.6) 1,371 (56.4) 
Manual Occupation (n, (%)) 163 (49.5) 175 (56.1) 241 (61.2) 433 (53.3) 146 (48.7) 111 (54.2) 75 (57.3) 1344 (54.1) 
Widespread pain, ACR criteria  
(n, (%)) 
78 (23.7) 120 (38.5) 96 (24.4) 276 (34.0) 51 (17.0) 30 (14.6) 7 (5.3) 658 (26.5) 
Baseline pain score (0-10 NRS)$, 
Mean (SD) 
5.83 (2.2)#a 5.92 (2.3)#a 5.56 (2.3)£a 4.86 
(2.6)£a 
4.89 (2.3) 5.09 (2.2) 5.21 (2.2) 5.28 (2.4) 
Baseline function score (0-10 NRS)$, 
Mean (SD) 
4.42 (1.9)#b 4.39 (1.9)#b 5.63 (2.0)£b 4.03 
(2.4)£b 
3.61 (1.4) 4.70 (1.9) 3.61 (2.2) 4.36 (2.1) 
Number of pain sites, Median (IQR) 6 (2.5-11) 8 (3-13) 8 (5-12) n/a n/a 4 (3-6) 3 (1-4) 6 (3-10) 
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Anxiety/ 
Depression 
(EQ5D item 5) 
No  223 (68.2) 179 (60.3) 292 (74.3) 455 (56.6) 189 (63.2) 139 (68.8) n/a 1477 (63.6) 
Moderate  94 (28.8) 114 (38.4) 95 (24.2) 307 (38.2) 107 (35.8) 57 (28.2) n/a 774 (33.3) 
Severe 10 (3.1) 4 (1.4) 6 (1.5) 42 (5.2) 3 (1.0) 6 (3.0) n/a 71 (3.1) 
Follow-up 
times 
1 6 weeks 3 months 3 months 4 months 6 weeks 6 weeks 4 weeks  
2 6 months 6 months 12 months 12 months 6 months 6 months 6 months  
3 12 months 12 months n/a n/a n/a 18 months 12 months  
 
* APEX trial: duration of pain was measured as <1; 1-5; 5-10; >10 years. A clinical diagnosis of osteoarthritis was part of the eligibility criteria, hence a duration of more than 
three months was assumed for all. #a: Mean (SD) pain score for all knee participants= 5.88 (2.2); #b: Mean (SD) function score for all knee participants= 4.40 (1.9); £a: Mean 
(SD) function score for all back participants= 5.09 (2.5); £b: Mean (SD) function score for all back participants= 4.55 (2.4). 
$ Higher scores indicate higher levels of pain or function. 
ACR = American College of Rheumatology criteria to classify presence of widespread pain; NRS= Numerical Rating Scale (on a scale of 0 to 10); IQR= Inter-Quartile Range; 
EQ5D = EuroQol, 5 Dimensional questionnaire; n/a = data not available (information on number of pain sites not collected in STarT Back/ PANTHER, EQ5D not collected in 
Tennis Elbow trial, no 3rd follow-up point in LBP, STarT Back or PANTHER trials) 
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Table 2: Univariable associations between pain site and short and long-term outcomes of change in pain and limitation in function# 
 
  Pain (0-10) Limitation in function (0-10) 
  Short term  
(≈3 months) 
Adjusted mean difference (95% 
CI) 
Long term  
(≥12 months) 
Adjusted mean difference 
(95% CI) 
Short term  
(≈3 months) 
Adjusted mean difference 
(95% CI) 
Long term  
(≥12 months) 
Adjusted mean difference 
(95% CI) 
Number of observations (n) 2,068 1,670 2,134 1,788 
Pain site Back (reference) 0 0 0 0 
Knee -1.58 (-1.83, -1.34)*** -1.85 (-2.12, -1.57)*** -1.39 (-1.59, -1.19)*** -1.62 (-1.83, -1.40)*** 
Neck -1.08 (-1.40, -0.76)*** n/a -0.95 (-1.22, -0.68)*** n/a 
Shoulder -0.34 (-0.70, 0.03) 1.21 (0.78, 1.64)*** -1.15 (-1.46, -0.85)*** 0.74 (0.40, 1.09)*** 
Elbow -0.58 (-1.02, -0.14)** 1.05 (0.58, 1.52)*** -0.43 (-0.80, -0.07) * 0.88 (0.49, 1.26)*** 
 
#Adjusted for baseline levels of pain and function 
*p<0.05, **p<0.01, ***p<0.001 
95% CI = 95% confidence interval; n= sample size used for each analysis. 
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Table 3: Multivariable associations (random effects linear regression, accounting for clustering within trials) between prognostic factors and outcomes of 
change in pain and limitation in function#  
   Pain (0-10) Limitation in function  (0-10) 
Potential prognostic factor  Short term Long term Short term Long term 
Number of observations (n) 1,875 1,477 1,936 1,593 
 Adjusted mean difference 
(95% CI) 
Adjusted mean difference 
(95% CI) 
Adjusted mean difference 
(95% CI) 
Adjusted mean difference 
(95% CI) 
Pain site Back (ref) 0 0 0 0 
Knee -0.98 (-1.30, -0.66)*** -1.07 (-1.45, -0.70)*** -0.77 (-1.04, -0.51)*** -0.74 (-1.03, -0.44)*** 
Neck -0.79 (-1.12, -0.47)*** n/a -0.66 (-0.94, -0.39)*** n/a 
Shoulder -0.37 (-0.73, -0.00)* 1.27 (0.83, 1.71)*** -1.19 (-1.50, -0.89)*** 0.76 (0.41, 1.11)*** 
Elbow n/a n/a n/a n/a 
Baseline pain score (0-10 NRS) 0.68 (0.63, 0.73)*** 0.74 (0.68, 0.80)*** -0.10 (-0.14, -0.05)*** -0.07 (-0.12, -0.02)** 
Baseline function score (0-10) -0.16 (-0.22, -0.10)*** -0.18 (-0.25, -0.11)*** 0.54 (0.49, 0.59)*** 0.56 (0.50, 0.62)*** 
Age (in years)  -0.02 (-0.03, -0.01)*** -0.02 (-0.03, -0.01)*** -0.02 (-0.02, -0.01)*** -0.02 (-0.03, -0.01)*** 
Gender Male 0 0 0 0 
Female 0.04 (-0.17, 0.25) 0.20 (-0.05, 0.46) -0.04 (-0.21, 0.13) 0.25 (0.05, 0.45)* 
Duration < 1 month  0 0 0 0 
1-3 months -0.42 (-0.76, -0.08)* -0.54 (-0.95, -0.14)** -0.25 (-0.53, 0.02) -0.29 (-0.61, 0.02) 
> 3 months -1.08 (-1.37, -0.78)*** -1.31 (-1.66, -0.96)*** -0.75 (-0.99, -0.51)*** -1.03 (-1.30, -0.76)*** 
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# All associations have also been adjusted for treatment category (intervention, sham/placebo, control), and every other variable listed in the table. n= sample size used for 
each analysis; 95% CI= 95% Confidence Interval; NRS= Numerical Rating Scale (on a scale of 0 to 10); ACR = American College of Rheumatology criteria to classify presence of 
widespread pain; EQ5D = EuroQol, 5 Dimensional questionnaire; n/a = data not available (EQ5D not collected in Tennis Elbow trial, therefore Tennis Elbow participants were 
not included in the multivariable analysis). 
*p<0.05, **p<0.01, ***p<0.001 
  
Manual work Non-Manual  0 
  
0 0 0 
Manual -0.33 (-0.53, -0.12)*** -0.34 (-0.59, -0.08)** -0.38 (-0.55, -0.21)*** -0.37 (-0.57, -0.17)*** 
Widespread Pain 
(ACR criteria) 
No 0 0 0 0 
Yes -0.39 (-0.62, -0.16)*** -0.55 (-0.83, -0.27)*** -0.39 (-0.58, -0.19)*** -0.56 (-0.78, -0.34)*** 
Mood: anxiety/ 
depression (EQ-
5D, item 5)  
No  0 0 0 0 
Moderate  -0.16 (-0.38, 0.06) -0.30 (-0.56, -0.03)* -0.11 (-0.29, 0.07)** -0.37 (-0.58, -0.16)** 
Severe  -0.64 (-1.26, -0.03)* -0.45 (-1.19, 0.29) -1.04 (-1.53, -0.54)*** -0.54 (-1.11, 0.03) 
Constant  1.06 (0.50, 1.61) 1.33 (0.64, 2.03) 1.59 (1.13, 2.04) 1.81 (1.27, 2.35) 
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Table 4: Significant interactions of pain site with potential prognostic factors (each interaction term has been individually added to the multivariable 
random effects model (random intercept for trial), one at the time)  
 
 Pain (0-10) Limitation in function (0-10) 
 Short term Long term Short term Long term 
Potential interactions Coefficient (95% CI) 1 Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) 
Pain Back 0 0 0 0 
Knee -0.13 (-0.24, -0.03)* -0.19 (-0.31, -0.07)** -0.09 (-0.18, -0.00)* -0.17 (-0.26, -0.07)** 
Neck 0.03 (-0.11, 0.16) n/a 0.00 (-0.11, 0.11) n/a 
Shoulder 0.15 (-0.01, 0.30) 0.17 (-0.01, 0.35) 0.08 (-0.05, 0.21) 0.11 (-0.03, 0.25) 
Function Back 0 0 0 0 
Knee -0.24 (-0.36, -0.12)*** -0.21 (-0.35, -0.07)** -0.26 (-0.36, -0.16)*** -0.26 (-0.37, -0.15)*** 
Neck -0.14 (-0.35, 0.07) n/a -0.17 (-0.35, 0.01) n/a 
Shoulder 0.15 (-0.03, 0.32) 0.16 (-0.05, 0.36) 0.01 (-0.16, 0.13) -0.02 (-0.19, 0.14) 
Age Back 0 0 0 0 
Knee -0.02 (-0.05, 0.00) -0.01 (-0.04, 0.01) -0.02 (-0.04, 0.00) -0.01 (-0.03, 0.01) 
Neck 0.02 (-0.00, 0.04) n/a 0.01 (-0.01, 0.02) n/a 
Shoulder -0.02 (-0.05, -0.00) 0.01 (-0.03, 0.04) -0.02 (-0.04, 0.00) 0.02 (-0.01, 0.04) 
Manual work Back 0 0 0 0 
Knee -0.66 (-1.14, -0.18)** -0.65 (-1.19, -0.10)* -0.23 (-0.63, 0.17) -0.31 (-0.74, 0.12) 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Neck -0.32 (-0.93, 0.29) n/a 0.04 (-0.47, 0.55) n/a 
Shoulder -0.13 (-0.83, 0.56) 0.07 (-0.76, 0.90) -0.13 (-0.71, 0.45) -0.10 (-0.77, 0.56) 
Depression/ 
Anxiety 
Back 0 0 0 0 
Knee (Mod) -0.16 (-0.68, 0.35) -0.03 (-0.62, 0.55) -0.25 (-0.68, 0.18) -0.22 (-0.69, 0.24) 
Knee (Sev) -0.10 (-1.64, 1.43) -0.11 (-1.83, 1.60) -0.52 (-1.76, 0.71) -0.71 (-2.08, 0.66) 
Neck (Mod) 0.71 (0.07, 1.36)* n/a 0.25 (-0.29, 0.79) n/a 
Neck (Sev) -0.82 (-3.46, 1.82) n/a -1.62 (-3.83, 0.60) n/a 
Shoulder (Mod) 0.05 (-0.72, 0.81) 0.30 (-0.64, 1.23) -0.06 (-0.70, 0.58) -0.02 (-0.77, 0.73) 
Shoulder (Sev) -0.45 (-2.42, 1.52) 0.42 (-1.93, 2.78) -1.20 (-2.85, 0.44) -0.31 (-2.22, 1.60) 
Duration Back 0 0 0 0 
Knee (1-3) -1.33 (-3.16, 0.50) -1.20 (-3.44, 1.05) -1.35 (-2.89, 0.18) -1.57 (-3.19, 0.05) 
Knee (3+) -1.03 (-2.64, 0.58) -2.15 (-4.16, -0.15)* -0.88 (-2.23, 0.47) -1.58 (-3.00, -0.16)* 
Neck (1-3) 0.03 (-1.36, 1.42) n/a -0.11 (-1.27, 1.05) n/a 
Neck (3+) 0.82 (-0.44, 2.09) n/a 0.63 (-0.43, 1.69) n/a 
Shoulder (1-3) -0.60 (-1.46, 0.27) -0.34 (-1.38, 0.69) -0.55 (-1.27, 0.16) 0.38 (-0.44, 1.20) 
Shoulder (3+) -0.11 (-0.99, 0.77) 0.08 (-0.97, 1.14) -0.27 (-1.00, 0.46) 0.41 (-0.42, 1.24) 
Gender Back 0 0 0 0 
Knee 0.47 (-0.02, 0.96) 0.25 (-0.31, 0.81) 0.21 (-0.19, 0.62) 0.20 (-0.24, 0.64) 
Neck 0.08 (-0.55, 0.70) n/a -0.00 (-0.53, 0.52) n/a 
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Shoulder  0.62 (-0.07, 1.32) 0.62 (-0.21, 1.45) 0.31 (-0.27, 0.89) 0.76 (0.09, 1.43)* 
Widespread 
pain 
Back 0 0 0 0 
Knee 0.33 (-0.20, 0.85) 0.28 (-0.31, 0.87) 0.19 (-0.24, 0.62) -0.01 (-0.47, 0.46) 
Neck 0.17 (-0.60, 0.94) n/a 0.24 (-0.40, 0.89) n/a 
Shoulder  0.05 (-0.92, 1.02) 0.03 (-1.11, 1.94) -0.74 (-1.53, 0.05) -0.33 (-1.24, 0.57) 
 
*p<0.05, **p<0.01, ***p<0.001 
1 The coefficient reflects the additional effect on pain or functional limitations of both the predictor and pain in a specific site, above and beyond the combined 
effects of pain site and predictor alone (negative coefficient indicates that the interactions strengthens the combined effect on change in pain/function if the coefficient is 
negative in the previous table (Table 3) (similar for positive coefficients), however, contrasting coefficient (positive in Table 3 but now negative) indicates weakening of the 
combined effect)  
 
 95% CI= 95% Confidence Interval; n/a= data not available (no longer term follow-up collected in PANTHER trial) 
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Figure 1. The course of pain intensity (mean scores, 0-10) for each trial  
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Figure 2. The course of limitation in function (mean scores, 0-10) for each trial 
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Appendix 1: Additional information about included studies 
 
 APEX TOPIK LBP StarT Back PANTHER SPIRIT Tennis Elbow 
Inclusion 
criteria 
Adults aged 50y or 
older with knee 
pain and a clinical 
diagnosis of knee 
OA 
 
Adults aged 55y 
and over consulting 
GP with knee pain, 
stiffness or both in 
one or both knees 
Adults aged 18-64 
years consulting 
their GP for the 
first or second 
time with non-
specific LBP of less 
than 12 weeks 
duration 
 
Adults aged at 
least 18 years 
with back pain of 
any duration, 
with or without 
associated 
radiculopathy  
 
Adults aged 18 
years or older 
with a clinical 
diagnosis of 
nonspecific neck 
pain (new 
episode) referred 
by physio by their 
GP 
 
Adults aged 18 
years and over 
consulting their 
GP with a new 
episode (no 
previous 
consultation in 
the last 12m) of 
unilateral 
shoulder pain 
Adults aged 18-70 
years who 
consulted GP with 
a new episode (no 
previous 
consultation in last 
12m) of lateral 
epicondylitis 
Time period of 
recruitment 
November 2003-
October 2005 
May 2001-March 
2004 
July 2000-July 
2002 
June 2007-
November 2008 
June 2000-June 
2002 
June 1998-
March 2000 
November 1995-
December 1997 
Participation 
rate 
GP referrals=1061; 
352 randomised; 
351 received 
allocated 
intervention 
 
Retrospective 
record review + GP 
referrals = 691; 325 
randomised; 311 
received allocated 
intervention 
544 assessed; 402 
randomised; 315 
received allocated 
intervention 
1573 assessed; 
851 randomised 
 
735 assessed; 350 
randomised; 332 
received 
allocated 
intervention 
237 referred; 
207 
randomised; 
192 received 
treatment 
182 referred; 164 
randomised; 156 
received 
treatment 
Loss to follow-
up 
At 6w, 18 lost to 
follow-up; at 6m, 
21 lost to follow-
up; at 12m, 40 lost 
At 3m, 44 lost to 
follow-up; 6m, 40 
lost to follow-up; 
12m, 53 lost to 
At 3m, 83 lost to 
follow-up; at 12m, 
73 lost to follow-
up  
At 4m, 162 lost 
to follow-up 
(withdrawals and 
non-responders); 
at 12, 40 lost to 
At 6w, 29 lost to 
follow-up (non-
responders) and 9 
missing data on 
outcome 
At 6w, 9 lost to 
follow-up; at 
6m, 2 lost to 
follow-up 
1 lost to follow-up 
at 12m in control 
arm 
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to follow-up  
 
ITT analysis  
follow-up  
 
ITT analysis 
 
ITT analysis 
 
follow-up 
(withdrawals and 
non-responders)  
 
ITT analysis  
(Northwick Park); 
at 6m, 25 lost to 
follow-up (non-
responders) and 
10 missing data 
on outcome 
 
